scispace - formally typeset
D

Douglas Galasko

Researcher at University of California, San Diego

Publications -  497
Citations -  72486

Douglas Galasko is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 114, co-authored 437 publications receiving 62031 citations. Previous affiliations of Douglas Galasko include Harvard University & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

Ian G. McKeith, +45 more
- 27 Dec 2005 - 
TL;DR: The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them as mentioned in this paper.
Journal ArticleDOI

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop

TL;DR: This work identified progressive disabling mental impairment progressing to dementia as the central feature of DLB, and identified optimal staining methods for each of these and devised a protocol for the evaluation of cortical LB frequency based on a brain sampling procedure consistent with CERAD.
Journal ArticleDOI

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

TL;DR: The revised criteria for behavioural variant frontotemporal dementia improve diagnostic accuracy compared with previously established criteria in a sample with known frontotmporal lobar degeneration and reflect the optimized diagnostic features, less restrictive exclusion features and a flexible structure that accommodates different initial clinical presentations.
Journal ArticleDOI

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

TL;DR: It is proposed that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease.